Cell-specific CRISPR/Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins

Mareike D. Hoffmann, Sabine Aschenbrenner, Stefanie Große, Kleopatra Rapti, Claire Domenger, Julia Fakhiri, Manuel Mastel, Roland Eils, Dirk Grimm, Dominik NiopekbioRxiv 2018 · DOI

TL;DR

This paper presents a novel "Cas-ON" switch that allows CRISPR/Cas9 gene editing to be activated only in specific cell types, using microRNA (miRNA) signatures as the trigger. This system leverages anti-CRISPR (Acr) proteins, which normally inhibit Cas9, to create a conditional ON state, paving the way for safer and more targeted CRISPR-based therapies.

What Problem Does This Paper Address?

CRISPR/Cas9 technology holds immense promise for treating genetic diseases, but its widespread application, especially in vivo, is hampered by a lack of specificity. Delivering CRISPR components can lead to unintended edits in off-target cells, raising concerns about safety and side effects. The challenge is to precisely control when and where CRISPR/Cas9 is active, ensuring it only functions in the intended cells or tissues. Existing methods for controlling CRISPR activity often lack sufficient precision or dynamic range for therapeutic applications.

Methods

The core innovation is a "Cas-ON" switch that uses miRNA-regulated expression of anti-CRISPR (Acr) proteins. Here's how it works:

  • miRNA Targeting: Acr proteins are engineered with target sites for specific miRNAs in their 3' untranslated region (3'UTR). These miRNAs are chosen because they are highly abundant in particular cell types (e.g., miR-122 in liver cells, miR-1 in muscle cells) but absent or low in others.
  • Conditional Acr Expression: In cells where the target miRNA is present, the miRNA machinery degrades the Acr mRNA, leading to low levels of Acr protein.
  • Cas9 Activation: Acr proteins are potent inhibitors of Cas9. When Acr levels are low (in the target cells), Cas9 is free to perform its gene editing or activation functions.
  • OFF-Target Inhibition: In cells lacking the specific miRNA, the Acr mRNA is translated efficiently, producing high levels of Acr protein. This Acr then binds to and inhibits Cas9, preventing any unintended activity.
  • Modularity: The system was demonstrated to be modular, working with different Cas9 variants (full-length, split, and dCas9-VP64 for gene activation) and even with a different Cas9 orthologue (NmeCas9) and its cognate inhibitors.
  • Delivery: Adeno-associated virus (AAV) vectors were used for efficient delivery of the Cas9, sgRNA, and Acr components, enabling in vivo studies.

Datasets

Not discussed in the paper. The study relies on cell lines (HeLa, HEK293T, Huh-7, HL-1) and in vivo models (implied by the discussion of AAV delivery for therapeutic applications).

Key Insights and Ideas

  • miRNAs as Cellular Barcodes: The study elegantly leverages the cell-type-specific expression patterns of miRNAs as natural "barcodes" to control gene editing.
  • Anti-CRISPRs as Conditional Inhibitors: Acr proteins, typically viewed as inhibitors, are repurposed as crucial components of a conditional "ON" switch, rather than just a simple "OFF" mechanism.
  • Dynamic Range Tuning: The system's activity (ON/OFF ratio) can be finely tuned by adjusting the dose of the Acr vector or the strength of its promoter, offering flexibility for different applications.
  • Broad Applicability: The modular design suggests this approach can be adapted to various CRISPR/Cas orthologues and cell types for which specific miRNAs and cognate Acrs are known.

Key Results

  • Hepatocyte-Specific Editing: The system successfully achieved miR-122-dependent activation of Cas9 in Huh-7 (hepatocyte-like) cells, leading to efficient genome editing at target loci (EMX1, CCR5, AAVS1) with a dynamic range of up to 16-fold. Cas9 activity was suppressed in HeLa (non-hepatocyte) cells.
  • Myocyte-Specific Editing: Similarly, miR-1-dependent activation of Cas9 was demonstrated in HL-1 (myocyte) cells for editing the Rosa-26 locus, with potent editing observed in the presence of the miR-1-targeted Acr construct.
  • dCas9-VP64 Activation: The Cas-ON switch was also effective in controlling dCas9-VP64 for gene activation, showing miR-122-dependent luciferase expression with a dynamic range of up to 114-fold.
  • NmeCas9 Control: The system was successfully adapted to control NmeCas9, achieving miR-122-dependent editing with a dynamic range of up to 24-fold.
  • Robust Inhibition: In off-target cells, Cas9 activity was effectively inhibited, demonstrating the specificity of the switch.

Limitations and Future Work

  • Acr Vector Dose: The authors note that the Acr vector dose is critical. Too high a dose can lead to significant suppression even in target cells, while too low a dose results in insufficient inhibition in off-target cells. This requires careful optimization.
  • RNAi Machinery Capacity: High doses of Acr vector might saturate the RNAi machinery, potentially affecting the system's performance.
  • Toxicity and Immune Response: The authors acknowledge that potential toxicity or immune reactions from Acr overexpression in vivo need careful investigation before clinical translation.
  • miRNA Pool Sequestration: To avoid depleting endogenous miRNA pools, coupling the system to vector self-inactivation is suggested for future work.
  • Expanding Cell Type Coverage: The authors anticipate that discovering more cell-specific miRNAs and their cognate Acrs will further expand the utility of this strategy to a wider range of cell types (e.g., neurons, hematopoietic cells).
  • Combination Therapies: Integrating this system with other control mechanisms (e.g., chemical triggers, light-inducible systems) could lead to even more precise genome perturbations.

Summary updated

Abstract

ABSTRACT The rapid development of CRISPR/Cas technologies brought a personalized and targeted treatment of genetic disorders into closer reach. To render CRISPR-based therapies precise and safe, strategies to confine the activity of Cas(9) to selected cells and tissues are highly desired. Here, we developed a cell type-specific Cas-ON switch based on miRNA-regulated expression of anti-CRISPR (Acr) proteins. We inserted target sites for miR-122 or miR-1, which are abundant specifically in liver and muscle cells, respectively, into the 3’UTR of Acr transgenes. Co-expressing these with Cas9 and sgRNAs resulted in Acr knockdown and correspondingly in Cas9 activation solely in hepatocytes or myocytes, while Cas9 was efficiently inhibited in off-target cells. We demonstrate control of genome editing and gene activation using a miR-dependent AcrIIA4 in combination with different Streptococcus pyogenes ( S py) Cas9 variants (full-length Cas9, split-Cas9, dCas9-VP64). Finally, to showcase its modularity, we adapted our Cas-ON system to the smaller and more target-specific Neisseria meningitidis (Nme) Cas9 orthologue and its cognate inhibitors AcrIIC1 and AcrIIC3. Our Cas-ON switch should facilitate cell-specific activation of any CRISPR/Cas orthologue, for which a potent anti-CRISPR protein is known.
BibTeX
@misc{hoffmann2018cell,
  author = {Mareike D. Hoffmann and Sabine Aschenbrenner and Stefanie Große and Kleopatra Rapti and Claire Domenger and Julia Fakhiri and Manuel Mastel and Roland Eils and Dirk Grimm and Dominik Niopek},
  title = {{Cell-specific CRISPR/Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins}},
  year = {2018},
  doi = {10.1101/480384},
  howpublished = {bioRxiv},
}
Figure